New markers for the detection of polycystic ovary syndrome by Sharif, Elham & Alwakeel, Mariam
Submit Manuscript | http://medcraveonline.com
Abbreviations: PCOS, polycystic ovary syndrome; IRS1, 
insulin receptor substrate 1; SHBG, sex hormone-binding globulin; 
TNF, tumor necrosis factor; IL-6, interleukin-6; LH, luteinizing 
hormone; FSH, follicle stimulating hormone; GnRH, gonadotropin-
releasing hormone; AMH, anti-müllerian; BPA, bsphenol A 
Introduction
Polycystic Ovary Syndrome (PCOS) is a highly prevalent, 
complex genetic disorder of the endocrine system in women. There 
have been various criteria suggested for diagnosis, although there are 
2 most accepted criteria: as suggested by the 1990 NIH – National 
Institute of Child Health and Human Development Conference of 
PCOS, where the presence of hyperandrogenism, hyperandrogenemia 
and oligoovulation, followed by exclusion of any other disorder is 
considered diagnostic for PCOS, or as suggested by the broader 2003 
Rotterdam consensus, in which presence of any 2 of the 3 above-
mentioned symptoms, followed by exclusion of other endocrinopathies 
is considered diagnostic for PCOS. Following the NIH criteria, 
about 10% of women globally are diagnosed with PCOS, while the 
Rotterdam criteria gives a higher percentage.1,2 This makes PCOS the 
most common human disorder and the most common single disorder 
of reproductive women. Although it was previously assumed that 
PCOS had relevance only in cases of fertility, it has now been shown 
to cause various long-term risks, such as hyperinsulinism, diabetes 
mellitus, cardiovascular disease and other morbidities.3,4
Pathophysiology
Alterations that occur in women with PCOS can be due to 
several predisposing factors; among these contributors are genetic 
and epigenetic variations. Environmental factors play a weaker role, 
mainly in worsening insulin resistance.
This complex metabolic disorder has no definitive pathway for 
explaining all the internal and external symptoms associated. However, 
studies have revealed a general understanding of the pathophysiology 
of the disorder. In PCOS patients, the primary defects are seen from 
two perspectives in the body, insulin resistance and relative LH/FSH 
levels.5 Rhesus monkeys and sheep were used as animal models 
of PCOS by exposing them to elevated levels of androgens during 
gestation. Evidence from these models suggested that developmental 
programming by androgen has a role in the deposition of abdominal 
fat and developing resistance to insulin.6 Many PCOS patients may 
develop insulin resistance; which means that the cells in their bodies 
fail to respond to the insulin hormone, and therefore, fails to take up 
the glucose. Since glucose is not utilized for energy production, it is 
stored in the body, resulting in weight gain. Eventually, excess insulin 
in the body will stimulate the ovaries to increase androgen production. 
This leads to oligo-ovulation (irregular ovulation) or anovulation 
(the absence of ovulation). Some typical insulin target organs, such 
as adipose tissue and muscles, are affected by insulin resistance, 
which makes it tissue-selective. Serine phosphorylation of the insulin 
receptor and of insulin receptor substrate 1 (IRS1) is markedly 
increased in muscles, causing a dysfunction in insulin signaling and 
in activation of mitogen-activated protein kinases MEK1 and MEK2.7 
Other organs like the ovary are spared and not affected by insulin 
resistance. 
Insulin resistance in PCOS is also associated with an increase of 
testosterone bioactivity by reducing the synthesis of sex hormone-
binding globulin (SHBG) in the liver (which is inhibited by insulin).5 
It is very likely among women with PCOS to have slight differences 
in fat distribution. According to studies, strong evidence indicates 
that adipocytes are abnormal in those patients, promoting insulin 
resistance and subclinical inflammation. For instance, adipocytes 
derived from patients with PCOS tend to have suppressed insulin-
mediated glucose transport by the action of inflammatory cytokines 
such as tumor necrosis factor (TNF) and Interleukin-6 (IL-6). Women 
with PCOS appear to have enlarged adipocytes, lower lipoprotein 
lipases activity and impaired catecholamine-induced lipolysis.
Furthermore, the two main pituitary hormones that orchestrate 
major changes in the body are Luteinizing hormone (LH), and 
Follicle stimulating hormone (FSH). These hormones are essential 
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Abstract
Polycystic Ovary Syndrome (PCOS) is a highly prevalent, complex genetic disorder 
of the endocrine system in women. Alterations that occur in women with PCOS can 
be due to several predisposing factors; among these contributors are genetic and 
epigenetic variations. Environmental factors play a weaker role, mainly in worsening 
insulin resistance. Enzyme, protein and genetic markers can depend as a biochemical 
diagnosis of PCOs. The genetic markers have been identified to be related to PCOS 
wasn’t useful for early diagnosis, which can only be used to confirm PCOS in 
patients already exhibiting the definitive symptoms. Protein and enzyme markers are 
commonly used for prognosis and monitoring the patient to prevent the development 
of the complications of PCOS. Proteins of the adipose tissue have been found to be 
greatly related to insulin resistance and the development of PCOS. The nature of 
enzymes and proteins of instability and easily degradable have prevented sufficient 
research from being carried out on them. Therefore, the diagnosis of PCOS relies on 
the analysis of multiple factors. 
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for reproduction. LH stimulates the production of androgen substrates 
which are then converted to create sex hormones such as testosterone 
and estrogen. In normal situations, synchronized signals between 
gonadotropins and factors produced in the developing follicle of the 
ovary result in ovulation. In women with PCOS, the growth of the 
follicle is arrested at an early antral stage, this results in follicular 
maturation arrest, accumulation of small antral follicles within the 
periphery of the ovary, giving it the polycystic morphology. FSH 
stimulates the growth of the ovarian follicle to allow maturation of the 
egg before it releases. It is important for FSH and LH to be in precise 
balance to avoid complications. Normally, during the beginning of 
menstruation cycle, FSH is higher than LH. However, in PCOS, this is 
reversed, and the release of gonadotropin-releasing hormone (GnRH) 
from the hypothalamus is often disturbed leading to hypersecretion of 
LH.4 Initially, instead of a higher FSH, there is an increase of the level 
of LH which produces an excess of androgen substrates that leads to 
elevated testosterone levels, which is associated with excess body and 
facial hair. 
Although serum follicle-stimulating hormone levels remain 
normal, follicles appear to be more resistant to FSH in PCOS patients. 
This could be due to an increase of intra-ovarian and anti-müllerian 
(AMH) hormone levels; high levels of AMH inhibits FSH action as 
well as recruitment of more primordial follicles.4 Thus, the ovaries are 
not stimulated adequately for maturation, and eventually ovulation. 
This is the reason why women with PCOS have difficulty conceiving 
and experience irregular menstruation cycles. 
Moreover, the observed increased production of androgen in 
PCOS is primarily due to stimulated synthesis of the hormone by 
follicular theca cells, which show high expression of multiple genes 
encoding steroidogenic enzymes.8 Further evidence supports that in 
some patients with PCOS, excess ovarian androgen is genetically 
determined. This has been reported after conducting some studies on 
theca cells obtained from patients and observing that DENND1A, a 
candidate gene, was overexpressed.
It is also observed in PCOS patients that the gene that encodes 
for the rate-limiting enzyme (CYP17A1) is elevated in theca cells 
obtained from patients. Those cells are more responsive to insulin and 
LH in terms of androgen secretion in patients rather than cells obtained 
from healthy individuals. In addition, reducing hepatic synthesis of 
SHBG due to hyperinsulinemia contributes to hyperandrogenism, 
which in turn leads to increased testosterone fractions. Adrenocortical 
dysfunction is also suggestive of hyperandrogenism as a secondary 
source along with excess androgen from ovaries as the primary source. 
Hirsutism is a consequence of excess androgen secretion. Because 
of testosterone and dihydrotestosterone stimulation of ornithine 
decarboxylase synthesis in the hair follicle, this stimulates the 
production of polyamine. These amines are necessary for cellular 
proliferation, including hair growth in the follicles.7
As for the environmental factors, expression of PCOS is affected 
by lifestyle changes. For instance, greater body weight and dietary 
saturated fat intake worsens metabolic and reproductive abnormalities. 
However, losing weight lowers androgen and insulin circulating 
levels, while enhancing hirsutism, as well as ovulatory dysfunction.9
Another factor could be endocrine disrupting chemicals, which 
can alter the metabolic and ovarian functions, resulting in PCOS-like 
symptoms. One of these chemical that is detected in PCOS patients is 
Bisphenol A (BPA), an estrogenic industrial plasticizer. Accumulation 
of BPA in susceptible women might increase the severity of PCOS 
phenotype expression.10
PCOS markers 
The definition and diagnosis of PCOS varies from lab to lab, and 
country to country. While the European criteria for diagnosis depend 
upon an abnormal appearance of the ovaries, the North American 
criteria for diagnosis depend upon various biochemical evidences of 
hyperandrogenism/hyperandrogenemia. 
The biochemical diagnosis can depend upon enzyme, protein and 
genetic markers. In this section, the various markers used for PCOS 
diagnosis, their advantages and disadvantages are discussed. 
Studies have shown a strong correlation between genetic 
factors and developing PCOS, and it shows an autosomal dominant 
inheritance scheme. Usually, there is a 30-50% chance that a woman 
might develop PCOS if one of her family members is affected. 
Twin studies indicate that monozygotic twin sisters have twice 
as high chance of developing PCOS as dizygotic twins. Up until 
now, researchers have identified around 100 susceptibility genes 
associated with PCOS.4 However, many studies indicate that it may 
have ontogenetic characteristics. Even though inheritance shows a 
strong familial relationship, the phenotypic manifestation among 
same family members may differ.11 According to Shaikh, Dadachanji, 
and Mukherjee (2014), the genetic factor in PCOS is not the only 
agent that contributes to this disease; environmental factors and other 
abnormalities also play a role in the development of this disease. 
PCOS also shows a strong relationship with many other disorders, 
like hyperinsulinemia and hyperandrogenemia, which tells us that 
it is a heterogenic syndrome. Because of this, the investigation on 
PCOS genetic background needs the knowledge of other disorder’s 
molecular basis.12 PCOS has been assumed to be associated with 
various genes regulating insulin function and androgen synthesis. 
One of the most important correlated diseases is insulin resistance, 
which is described as the inability of host cells to respond to insulin 
secretion. A brief look at insulin function suggests that it is involved in 
a complex cascade that activates various cellular receptors, including 
INSR and IGF-1 receptors. INSR is a major insulin receptor than has 
a tetrameric structure consisting of two alpha and two beta subunits. 
The activation of INSR is mediated mainly by insulin which triggers 
tyrosine kinase activation, which in turn activates a long complex 
signaling cascade. A study that was done by Urbanek, et al.,13 on 37 
PCOS candidates’ genes showed that there is post signaling defect of 
INSR in their skeletal muscles and adipose tissues. One of the markers 
that showed a strong association with INSR defect and associated 
with PCOS is D19S884, which lies on chromosome 19 P13.2.13
Another molecule that is correlated with INSR activation is IRS. 
The phosphorylation of IRS allows INSR to communicate with 
insulin signaling mediators like PI3K, Fyn and Crk. A study that 
was done by Dunaif, Wu, Lee, and Diamanti-Kandarakis,10 showed 
that PCOS candidates have defect in their IRS molecules in their 
skeletal muscles.14 Studies also showed that the polymorphisms 
in IRS-1 and IRS-2 are associated with many PCOS cases, especially 
in women from Italy, Japan, Greek, Turkey and other different 
populations.
ENPP1, Calpain-10 and PPARγ are also other molecules associated 
with PCOS that mediate insulin signaling. The complication with 
these markers is polymorphism. According to the study above, these 
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markers did not manifest in all PCOS cases, and their exact role in 
PCOS pathogenesis is not yet understood properly.
As indicated earlier, PCOS is associated with many other 
disorders, as there are many studies which describe the influence of 
other disorders in PCOS’ pathogenesis.
Even though PCOS shows a variety of symptoms, the main 
characteristic is defects in hormonal secretion, i.e., there is an 
abnormal quantity of male hormones which leads to faults in 
menstruation and the formation of cyst on ovaries. To understand the 
genetic basis of PCOS, it is important to investigate the abnormalities 
in steroidogenesis in the molecular level.
One of the diagnostic features of PCOS, which is the abnormal 
elevation of circulating androgen, is due to the overexpression 
of theca cells in ovaries which are responsible for the production 
of androstenedione and testosterone. This is due to the increased 
transcription and mRNA stability of steroidogenic enzymes.
Historically, CYP17 has showed a correlation with 
hyperandrogenism. It transcribes P450c17α enzyme, which is the 
limiting step in androgen synthesis. According to a study of Rosenfield 
et al (1999), patients with hyperandrogenism and PCOS have an 
elevated P450c17α activity which may correlate with the massive 
androgen secretion. CYP17 is located on chromosome 10q24.3. Some 
studies suggest that the polymorphism of CYP17 may influence PCOS 
manifestation, but other studies failed to confirm this association. To 
date, the exact role of this gene has not been defined.
Another gene, CYP11A is considered as a candidate gene for 
PCOS and hyperandrogenism. CYP11A gene involved in the initial 
step of androgenesis; it encodes for the enzyme that cleaves the side 
chain of cholesterol, and prepares it for conversion into androgen. A 
polymorphism in this gene is defined by repeats of (tttta) at 528bp at 
CYP11A promoter. This genotype has been strongly associated with 
PCOS in 20 pedigree that express the disease.15
Although these genes showed a relationship with PCOS, many of 
them failed to be reliable in early diagnosis of PCOS. This is due 
to the absence of standard expression scheme among the population, 
and the presence of other genes that influence the expression of 
hyperandrogenism.
A recent study by Eisenberg et al.16 showed the possibility to screen 
the anovulatory women using serum miRNA20b and miRNA-429. The 
study involved 7 normally ovulating women, 15 normally ovulating 
women with pure male infertility factor, and 18 women with PCOS. 
The method of detection was RT-PCR. The results showed that women 
with PCOS and anovulatory conditions showed higher concentration of 
miRNA20b and miRNA-429 than spontaneously ovulating women.16 
miRNA play a role in the formation of the primordial follicles and 
regulate follicular development. It shows different concentration 
during the luteal cycles. miRNA can regulate gene expression by 
binding to the 3’ in the untranslated region of mRNA. This inhibits 
translation by making the target mRNA unstable. The exact role of 
miRNA in PCOS is not defined yet. However, a significant increase in 
specific miRNA has been manifested in follicular fluids and patients’ 
serum. A study tried to explain miRNA role in PCOS using rat 
model expression. The study used DHT to mimic hyperandrogenic 
levels in human. The analysis of the ovaries in these models showed 
hyper elevation of 72 miRNA compared to the control, where 17 
miRNA showed depression. Another study explained miRNA role in 
regulation apoptosis and differentiation in ovaries cells, and that may 
correlate with abnormal miRNA incidence in PCOS.17
Zao et al (2017) indicated that there could a relationship between 
the methylation of o-PPARGC1A promoter in leukocytes and 
mitochondrial DNA of PCOS patient. The cross –sectional study 
indicates that there is an elevation in the concentration of methylated 
PPARGC1A promoter in PCOS patient compared to normal control. 
It also indicates that there is depletion in mitochondrial DNA in PCOS 
compared to healthy women. The study suggests that there could be 
a relation between these markers and the metabolic abnormalities of 
PCOS patients. This suggestion is enhanced by the fact that most PCOS 
patients who had high methylated o-PPARGC1A promoter had high 
BMI too. Moreover, the study suggests that these markers associate 
with insulin and IRN concentration not only in PCOS, but also in non-
PCOS women. One of the explanations suggested by the study about 
the elevation of methylated PPARGC1A promoter in leukocytes is 
epigenetics. Androgen enhances the epigenetic alternation of patient 
genome, which inevitably causes hypermethylation of PPARGC1A 
promoters. PPARGC1A promoter in leukocytes and mitochondrial 
DNA play a remarkable role in human physiological process, including 
the maintenance of blood pressure and cholesterol regulation. Thus, 
the ratio of PPARGC1A promoter in leukocytes and mitochondrial 
DNA can be used as marker for metabolic risk in PCOS.
An enclosure of the genes most correlated with PCOS is not 
impossible. A study done by Panda, P. K., Rane, R., Ravichandran, R., 
Singh, S., & Panchal, H. (2016) indicated that there are 43 genes that 
are related to PCOS (Table 1).11
Recently some studies candidate probable markers for PCOS 
that may be used in future as definitive marker for screening and 
diagnosis. One of these markers is D19S884 marker which showed 
a high specificity to PCOS. It is a microsatellite that lies in 55 intron 
in fibrillin gene. The fibrillin gene functions on TGF-B regulation; 
however, their exact role in PCOS is not defined yet.
Another important gene is TCF7L2, which lies in type 2 diabetes 
locus. IRSN gene has also showed a strong relation with PCOS. For 
screening purposes, miRNA has shown to be of great value to detect 
anovulation patient; however, it can only define that there is a defect 
in patient ovulation cycle.11
As mentioned earlier, PCOS is a complex syndrome that correlates 
with many disorders, many of which arise from genetic backgrounds, 
especially insulin receptors abnormalities. However, due to many 
factors including polymorphism, environmental factors, and variation 
of causative agent in PCOS, the diagnostic value of these genetic 
markers may be useless in many cases. Many studies tried to find a link 
between PCOS and specific genes in patient’s genomes, while others 
tried to utilize the linkage studies to demonstrate a precise diagnostic 
tool for the disease. Some of the studies appeared successful in finding 
a significant marker, while others improved that this marker has no 
specificity or any important role in testing. This can be related to the 
different sensitivity and specificity used for the test. For instance, the 
POMC gene, rs12473543, was previously thought to be related with 
PCOS but after correction testing, it showed no significant value.
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Table 1 a summary of 43 genes that are found in PCOS patients including their accession name, PDB-ID and Unirprot ID
List of 43 Genes involved in PCOS with UNIPROT-ID. PDB-ID and chromosomal locations
Gene name Locus Organism Uniprot ID Accession number PDB-ID
CYP11A-cytochrome 
P450 side-chain 
cleavage enzyme 
(Marker Locus:015 
3520)
Chromosome 15: 
74,367,990-74,368,179 Homo P05108 P05108 3N9Y
  Sapiens    
Sex hormone binding 
globulin
Chromosome 17: 
7,613,946-7,633:383 Homo PO4278 ABY68008 1028
  Scptens    
Luteiniaing hormone 
choriogonadotropin 
receptor
Chromosome 2: 
48,708,77048.723,514 Homo P22888.4 P22888 1LUT
  Sapiens    
Follicle-stimulating 
hormone receptor
Chromosome 2: 
48,962,15749,154,537 Homo P23945 AAB26480 1XUN
  Sapiens    
Mothers against 
decapentaplegic 
homolog 4
Chromosome 18: 
51,028:394-51,085,045
Homo 13485 NP 005350 1DD1
  Sapiens    
Leptin
Chromosome 
7: 128,241:284-
128,257,628
Homo P41159 AAH69452 1_AX8
  &Ver.    
Leptin receptor
Chromosome 
1:65,420,652-
65,641,559
Homo P48357 AAB09673 3V60
  &piens    
Inhibin beta-B
Chromosome 
2: 120,346,143-
120,351,808
Homo P09529 AAH30029  
  Sapiens    
Inhibin beta-A
Chromosome 7: 
41,685,114-41,703,108 Homo P08476 AAH07858 1NYS
  Sapiens    
Inhibits A (gene symbol: 
INHA)
Chromosome 2, 219,5 
69:162-219,575,713 Homo P05111 P05111  
  &pi-ens    
Pro-opiomelanecortin Chromosome / 25,160,853-25,168,903 Homo P01189 P01189  
(gene symbol: POMC).  Segal.    
Uncoupling protein 
213
Chromosome 11: 
73,974,667-73,983,307 Homo P55851 P55851  
(gene symbol: UCP2 
+ 3)  Sapiens    
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List of 43 Genes involved in PCOS with UNIPROT-ID. PDB-ID and chromosomal locations
Melanocortin 4 
receptor
Chromosome 18: 
60,371,110-60,372,775
Homo P32245 AA092061 2IQP
  Sapiens    
Insulin-like growth 
factor I
Chromosome 
12: 102,395,867-
102,480:645
Homo P05019 CAA40342 1B9G
  Sapiens    
Insulin-like growth 
factor I receptor
Chromosome 15: 
98,64-8,971-98,964,530 Homo P08069 P08069 lIGR
  Sapiens    
Insulin-like growth 
factor binding protein1 
+ 3 (gene symbol: 
IGFBPI + 3)
Chromosome 7: 
45,888,35745:893,668
Homo P08833 P08833 1ZT3
  Sapiens    
Insulin gene VNTR 
(gene symbol: INS 
VNTR)
Chromosome 
11:2,159,779-2,161,341 Homo P01308 P01308 1A7F
  Sapiens    
17 b-hydroxysteroid 
dehodrogenase, type 
II Marker Locus: 
(HSD17B2)
Chromosome 16: 
82,035:004-82,098,534
Homo P37059 P37059  
  &piens    
17 b-hydroxysteroid 
dehydragenase, type 
III Marker Locus: 
(D951809)
Chromosome 9: 
96,235,306-96:302,152
Homo P37058 P37058  
  Scpiens    
3 b-hydroxysteraid 
dehydrogenase: type I 
and II Marker Locus: 
(D10514)
Chromosome 
1:119,507,198-
119,515,054
Homo P14060 P14060  
  Scpiens    
Steroidocenic acute 
regulatory- protein 
Marker Locus: 
(D051821)
Chromosome 8 3 
0,143,649-3 8:151,265 Homo P49675 P49675 10MG
  STrens    
Activin receptor 
1 Marker Locus: 
(D12S347)
Chromosome 
10: 102,479,229-
102,502711
Homo P61163 P61163  
  Scpiens    
Activin receptor 2A
Chromosome 
2:147,844517-
147,930,826
Homo P27037 P27037 3Q41
Marker Locus: 
(1)252335)  Sapiens    
Activin receptor 2B Chromosome 3: 3 8,453,851-3 8:493,142 Homo Q13705 13705 2136U
Marker Locus:(D3S 
1298)  Sapiens    
Table Continued
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List of 43 Genes involved in PCOS with UNIPROT-ID. PDB-ID and chromosomal locations
Inhibin C Marker 
Locus: (D1201691)
Chromosome 12 NC 
00001112
Homo P55103 P55103  
 (5743468557452060) Scpiens    
Follthlatm Marker 
Locus: (D5 5474)
Chromosome 
5:53,400,409-
53,487,134
Homo P19883 P19883  
  Sapiens    
Insulin receptor Chromosome 19: 7,112,255-7,294,034 Homo P06213 AAA59452 1GAG
(Marker Locus: MISR)  Sccoiens    
Insulin receptor Chromosome 19:4,903,0804,962,154 Homo 096T88 96188 2.FAZ
(Marker Locus: 
D192216)  &piens    
Insulin receptor Chromosome 19: 7,595,902-7,618:304 Homo 09PlY5.2 09P1 Y5 —
(Marker Locus: 
D192905)  &pions    
Insulin receptor Chromosome 19: 8,065,402-8,149:846 Homo Q75N90 Q75N90 —
(7arker Locus: 
D192884)  Scpions    
Insulin receptor Chromosome 19:8,520,790-8,577,577 Homo 160 160 —
(larker Locus: 
D192391)  Sapiens    
Insulin receptor Chromosome 19: 8,580,242-8,610:735 Homo Q9H324.2 Q9H324 —
(Marker Locus: 
D192906)  Sapiens    
Insulin receptor Chromosome 19: 13,906:201-13,930,879 Homo Q6P1NO Q6P1NO  
(Marker Locus: 
D192840)  Sapiens    
Insulin receptor Chromosome 19: 18,207:961-18,255,419 Homo Q08493 Q08493 1LXIT
(Marker Locus: 
D192212)  Sapiens    
Insulin receptor 
(Marker locus: 
D195410)
Chromosome 19: 
17,281:645-17,287,646
Homo 
sapiens
Q8N.A.G6 08NAG6
 
  
Insulin receptor 
substrate 1
Chromosome 
2: 226,731317-
226,799,759
Homo P35568 NP 5535 1 IRS
  Sapiens    
Peroxisome 
proliferator-activated 
receptor-comma
Chromosome 
3:12,287,368-
12.434,356
Homo P37231 P37231 1FM6
  Sapiens    
Mothers against 
clecapentaplegic 
homolog 4(gene 
symbol: MADH4)
Chromosome 18: 
51,028394-51,085,045
Homo 
sapiens
Q13485 Q13485.1
11:1131  
Androgen receptor Chromosome X: 
67,544,032-67:730,619
Homo P10275 P10275 1E3G
Table Continued
New markers for the detection of polycystic ovary syndrome 263
Copyright:
©2019 Sharif et al.
Citation: Sharif E, Alwakeel M. New markers for the detection of polycystic ovary syndrome. Obstet Gynecol Int J. 2019;10(4):257‒268. 
DOI: 10.15406/ogij.2019.10.00452
List of 43 Genes involved in PCOS with UNIPROT-ID. PDB-ID and chromosomal locations
(Marker Locus: _AR)  Sapiens    
CYP11A-cytochrome 
P450 side-chain 
cleavage enzyme
Chromosome 15: 
74,337:759-74,367,740
Homo P05108 P05108 3N9Y
Marker Locus: 
(D155519)  Sccoiens    
CYP17-
0ochrome P450 
17a-hydroxylasey17,20-
desmolase
Chromosome 
10: 102,830,531-
102,837:533
Homo P05093 P05093 2C17
Marker Locus: 
(D105192)
 Sccoiens    
CY?19-0o-chrome 
P450 aromatase
Chromosome 15: 
51,208:057-51,338,610
Homo P11511 P11511 1TQA
Marker Locus: (CYP19)  Sccoiens    
17 b-lrydmxysteroid 
dehydrogenase, type I
Chromosome 17: 
42,549:214-42,555,213
Homo P14061 P14061 1A27
Marker Locus: 
(D175934)  Sccoiens    
17 b-hydroxysteroid 
dehydrogenase, type 
LE Marker Locus: 
(HSD17B2)
Chromosome 16: 
82,035:004-82,098,534 Homo P37059 P37059 —
  &piens    
17 b-hydmxvsteroid 
dehydrogenase, type 
DI Marker Locus: 
(99S1809)
Chromosome 9: 
96,235,306-96:302,152 Homo P37058 P37058 —
Table Continued
Historical concepts about the correlation between PCOS and 
some genes like follistatin and lamin failed to act as a definitive 
diagnostic tool for the disease. None of these genes are conclusive 
for PCOS diagnosis, even though most of them were found in high 
prevalence among PCOS patients. Some of them have a known role 
in the disease while other’s role still ambiguous. The non-specificity 
and the overlapping symptoms between PCOS and other endocrinal 
abnormalities form a huge obstacle which the investigator must 
overcome to find a valuable genetic marker for PCOS.
Alteration in enzymes function either by inhibition or lack of 
function can affect the normal function of the body. Therefore, 
enzyme alteration in ovaries can lead to many symptoms; one of 
which is polycystic ovarian syndrome (PCOS). As discussed earlier, 
theca cells from polycystic ovaries show a significant increase in 
both androstenedione and progesterone production in vitro when 
compared to normal theca.18 This suggests that the putative defect 
in steroidogenesis occurs at or above the level of progesterone 
biosynthesis. The cholesterol side-chain cleavag enzyme, cytochrome 
P450scc, catalyses the conversion of cholesterol to pregnenolone, the 
first rate-limiting step at the start of the steroid hormone biosynthesis 
pathway.19,20 It is hypothesised that upregulation of this enzyme could 
lead to an increase in androgen production.
A second steroidogenic enzyme, aromatase (cytochrome 
P450arom), catalyses the conversion of the C19 steroids (androgens) 
to the C18 estrogens. Evidence for altered regulation of this enzyme 
in PCOS comes from the observation that granulosa cells from 
anovulatory polycystic ovaries are hyper-responsive to FSH in 
vitro, displaying significantly greater estradiol production compared 
to granulosa cells from normal ovaries.21 Conversely, two other 
studies have demonstrated cases in which aromatase deficiency was 
associated with hyperandrogenemia.22,23 These studies also suggest 
that an altered regulation of this enzyme may be involved in PCOS.
A study was conducted to investigate P450scc and P450arom 
enzymes as potential candidates for involvement in PCOS/MPB. The 
genes encoding P450scc (CYP11a) and P450arom (CYP19) are both 
located on the long arm of chromosome 15 at positions 15q24 and 
15q21.1 respectively. Given uncertainties regarding the segregation 
model for PCOS, both parametric and non-parametric linkage analyses 
were conducted in 20 PCOS/MPB pedigrees. Mutation screening of 
the promoter region of CYP11a was also carried out. Finally, using 
a CYP11a intragenic marker, an association study in a case-control 
data set of consecutively identified Europid women with PCOS and 
matched controls was carried out. Both parametric and non-parametric 
linkage analyses were carried out for each of the candidate loci using 
New markers for the detection of polycystic ovary syndrome 264
Copyright:
©2019 Sharif et al.
Citation: Sharif E, Alwakeel M. New markers for the detection of polycystic ovary syndrome. Obstet Gynecol Int J. 2019;10(4):257‒268. 
DOI: 10.15406/ogij.2019.10.00452
the GENEHUNTER program.24 The position and chromosomal order 
of the microsatellite markers was used in the analyses. Clear exclusion 
of the CYP19 locus was obtained as there was no evidence for excess 
allele sharing across the whole region.
The non-parametric results for the CYP11a locus provided evidence 
for excess allele sharing. The results from these data suggested that 
∼60% of the pedigrees may be linked to the CYP11a (ac)n/D15S169 
locus.
Since any pathogenic mutations in CYP11a are expected to lead to 
upregulation, mutation screening of the promoter region of CYP11a 
was carried out. This region is believed to contain multiple cAMP-
regulated elements, responsible for increasing basal transcriptional 
activity, and elements involved in repression of expression.25 PCR 
amplification, followed by direct sequencing analysis, was used 
to screen 1.85kb of sequence in ten affected and eight unaffected 
members of the pedigrees. No alterations to the published sequence 
were found in any individual apart from variation in the number 
of repeat units of the two microsatellite polymorphisms present in 
this region [a dinucleotide (ac)n repeat, and a pentanucleotide (tttta)
n repeat, at positions −1376 and −528 respectively from the ATG start 
of translation site]. Individuals in the case-control study were typed 
for the CYP11a (tttta)n marker. Four alleles were observed in our data 
set, alleles 216, 226, 236 and 241 with observed frequencies of 0.59, 
0.28, 0.04 and 0.09 respectively. In order to reduce multiple allele 
comparisons for infrequent alleles, individuals were allocated to two 
groups according to their genotype, those having at least one copy 
of the common, four-repeat unit alleles (designated 216+) and those 
with no 216 allele (designated 216-). An association between this 
polymorphism and serum testosterone levels was found in the total 
data set. The genotype distributions were compared of each quartile of 
serum testosterone level within the total data set, and the proportion of 
individuals with 216- genotypes in each quartile were (from highest to 
lowest) 0.44, 0.23, 0.18 and 0.13.
On subgroup analysis, the association between CYP11a genotype 
and testosterone was only evident in the women with PCOS. There 
was no significant difference between the mean testosterone levels of 
216- and 216+ individuals for either the normal controls or the a PCO 
groups. However, the numbers in these groups were small, raising the 
possibility of error.
 Next, the CYP11a genotype distributions were compared between 
subject groups. Since the association between serum testosterone 
levels and CYP11a genotype was only seen in the PCOS group, 
taking the entire data-set (including those without testosterone 
levels available), compared PCOS women with a combined normal 
control/a PCO group, and a significant difference in the distribution 
of genotypes between these groups was observed.
The data showed that the gene coding for aromatase (CYP19) can 
be excluded as a major determinant of risk for PCOS/MPB. In contrast, 
the linkage results for CYP11a (encoding side chain cleavage) provide 
support for the involvement of this gene in the etiology of PCOS. The 
association data demonstrated that allelic variants of CYP11a mediate 
the development of hyperandrogenemia, which is in turn associated 
with PCOS and hirsutism. The association of this gene with 
hirsutism and the lack of association with ovulatory status indicates 
that CYP11a predominantly has a role in the development of hirsutism 
in PCOS.
A significant association had been shown between alleles of 
the CYP11a (tttta)n marker and serum testosterone levels. It is feasible 
that allelic variants of this rate-limiting enzyme could influence the 
level of androgen production. This association however, can only 
be demonstrated in the PCOS group. The failure to demonstrate 
association in the aPCO (women with polycystic ovaries without any 
symptoms; silent) and normal groups may be due to small sample 
sizes. Alternatively, it may be that this locus has a modifying effect, 
interacting with other genetic and/or environmental factors controlling 
the development of the ovarian changes and thereby influencing the 
clinical presentation of PCOS.
CYP11a (tttta)n is present in the promoter region of CYP11a and 
sequencing analysis of the surrounding regions does not reveal any 
other mutations likely to have direct pathogenic effects. However, 
since only 1.85 kb of sequence was screened, the putative mutation 
could be located outside this region. Recently many gene-associated 
VNTRs (variable number tandem repeats) have been implicated in the 
regulation of the genes, such as the insulin gene VNTR (30). Also, 
direct association between alleles of a (tttta)n repeat polymorphism, 
present in the 5′ flanking region of the apolipoprotein(a) gene, and 
plasma levels of Lp(a) has been demonstrated.26 Expression studies 
have shown a 5-fold higher transcriptional activity in constructs 
containing eight copies of the apolipoprotein(a) (tttta) repeat compared 
to those with nine copies.26
However, no regulatory function has been assigned to 
the CYP11a (tttta)n polymorphism, and further investigation of the 
promoter region of CYP11a is required to determine the relationship 
between the (tttta) repeat polymorphism and the regulation of this 
gene.
Allelic variants of CYP11a have a role in the etiology of 
hyperandrogenemia. This in turn may be sufficient to cause the altered 
ovarian morphology or may act in conjunction with other genetic 
factors to modify the phenotypic expression of PCOS.
It is not enough to use genetic markers or enzyme for definitive 
diagnosis of PCOS, as is evidenced by the fact that gene expression 
varies from individual to individual, and that the genes may manifest 
differently in aPCO individuals and PCOS patients. Moreover, 
different factors such as environment also control the phenotype. 
Many different protein markers are currently assessed in PCOS 
individuals, although most of them are used for prognosis, monitoring 
and to prevent further complications, such as cardiovascular disease. 
The pathogenesis of PCOS can be associated with elevated gut 
permeability. Obesity, irritable bowel syndrome and chronic fatigue 
syndrome are linked to an increase in gut permeability and contribute 
to the development of the disease. Regulation of gut permeability 
is reversibly regulated by Zonulin, a physiological mediator found 
in the counterpart of vibrio cholera zonula. This non-invasive 
biomarker is used to indicate gut permeability as it is increased in 
the small intestine and related to intestinal immunity. Its role in the 
indication of metabolic diseases has been recently recognized.27 To 
confirm the correlation between high levels of serum zonulin and the 
development of PCOS, anthropometric data were collected from the 
control and the experimental group, and the concentration of serum 
zonulin was measured by ELISA (sensitivity<0.01ng/ml). It has been 
confirmed that high levels of serum zonulin correspond to PCOS, 
and a strong relationship has been demonstrated between increased 
levels of serum zonulin and insulin resistance, dyslipidemia, and the 
severity of menstrual disorders. This study correlated the significance 
of gut permeability and PCOS, and reported that zonulin is elevated 
in PCOS group compared to non-PCOS participants; as speculated, 
gut permeability alterations result in compromising the intestinal 
barrier and facilitating the access of infectious agents leading to 
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overproduction of gamma interferon and interleukin-6, which in 
turn control the production of zonulin. Although several studies 
have been conducted to demonstrate the role of serum zonulin as a 
biomarker in the diagnosis of PCOS, the mechanistic link between the 
development of PCOS and zonulin remain unclear. This imitation can 
be improved by the measurement of cytokines such as b-1 interleukin, 
interleukin-6, and tumor necrosis factor.28
The visceral adipose tissue is one of the sites responsible for 
the secretion of adiponectin, an adipocytokine produced by mature 
adipocytes. It is known that the levels of serum adiponectin go down in 
obese individuals which leads to an increase in their insulin resistance, 
thus, developing polycystic ovary syndrome.29 The marker adiponectin 
and insulin resistance have been correlated to be associated with 
type 2 diabetes.18 A cross sectional observational research has been 
conducted to determine the degree of insulin resistance in patients with 
PCOS by measuring the level of serum adiponectin in urine samples 
via ELISA.30 It has been confirmed that there is relation between the 
concentration of serum adiponectin detected and the degree of insulin 
resistance in PCOS patients; decreased adiponectin levels reversely 
correlate with an increased degree of insulin resistance and BMI in 
PCOS patients. As discussed earlier, multiple metabolic diseases are 
hidden under polycystic ovary syndrome, the most significant ones 
being hyperinsulinemia and insulin resistance. In the above-mentioned 
study, it has also been demonstrated that type 2 diabetes mellitus 
in patients with PCOS is mainly due to decreased levels of serum 
adiponectin, as it increases their insulin sensitivity and obstructs the 
function of beta cells. Further, it confirmed that obese PCOS patients 
have lower levels of serum adiponectin compared to the group who 
exhibit normal weight. Despite the pathogenesis of PCOS still being 
debatable and controversial, it has been observed that low levels of 
adiponectin, hyperinsulinemia and hyperandrogenism contribute to 
the development of the disease.
Serum adiponectin level is considered an adequate biomarker in 
the diagnosis of PCOS and the degree of insulin resistance. It also aids 
doctors in prognosis and prediction of further complications, such as 
systemic morbidity of PCOS.20 
Leptin, tumor necrosis factor, alpha-interferon, ghrelin, retinol 
bindingprotein-4, resisten, visfatin and apelin are other molecules 
produced by the adipose tissue. These act as mediators involved in 
lipid metabolism atherosclerosis, immunity and inflammation, insulin 
sensitivity and many physiological processes.31 
Apelin, an adipokine secreted by the adipose tissue as a 
biologically active peptide, has been identified from the extracts of 
bovine stomach in both human and mice. It has been considered a 
marker for the diagnosis of PCOS since recent times, as it is involved 
in the pathogenesis of cardiovascular diseases and dyslipidemia. It 
is connected to insulin resistance with other markers: tumor necrosis 
factor, interleukin-6, C-reactive protein, Insulin-like growth factor and 
sex steroids. Apelin can be found in multiple organs including heart, 
brain, kidneys and lungs. It functions as an endogenous receptor ligand. 
Different levels and concentrations of serum apelin are associated 
with different stages of ovarian follicles. This biomarker affects water 
intake and hypothalamo-hypophyseal axis and the cardiovascular 
system.32 The conducted enzyme immune assay method was used to 
determine the level of plasma apelin, and it has been found that it is 
higher in PCOS patients compared to the control group: the increased 
concentrations of plasma apelin can be associated with androgenic 
obesity, hypothalamo-hypophyseal axis, polycystic ovaries, increased 
hip to waist ratio and in the case of impairment between LH/FSH 
interaction.33 However, due to the lack of sufficient data and studies 
regarding this adipokine, it cannot be used as a definitive diagnostic 
marker and other adipokines with similar properties are used instead, 
like visfatin and alpha tumor necrosis factor.18 
Although the pathogenesis of PCOS is somehow unclear, it is 
well known that it is caused by impaired folliculogenesis leading to 
oligo-ovulatory cycles, due to which high levels of Anti-Mullerian 
Hormone (AMH) are produced. AMH is secreted by granulosa cells 
found in the antral follicles, as part of the normal body physiological 
process, AMH should be decreased following the development of 
follicles. However, the opposite can happen due to pre-antral follicle 
proliferation and high production of follicular secretions which leads 
to PCOS. The discovery of AMH has avoided the need for invasive 
follicular phase ultrasound examination, because the detection of high 
levels of this biological marker is adequate in assessing an accurate 
diagnosis. It is coupled with other clinical features such as, mean 
ovarian volume, the duration of menstrual cycle and levels of serum 
aldosterone and testosterone.34
To rule out the significant role of AMH as a biological maker 
in diagnosing PCOS, an experiment was conducted to evaluate the 
levels of AMH in both PCOS patients and healthy individuals, where 
the AMH was measured by an enzymatically amplified two-sided 
immunoassay with a sensitivity of 0.006ng/ml.25 It was found that 
women with PCOS have triple the amount of serum AMH compared 
to healthy women, and these results are compatible with the results 
of several studies conducted previously that reported higher levels of 
AMH in PCOS women.
It can, therefore be concluded that in cases of polycystic 
ovary syndrome, the levels of AMH, in addition to LH/FSH ratio 
increase. However, LH/FSH ratio can be within the normal range in 
approximately 80% of patients presented with PCOS. Thus, AMH is 
considered the strongest marker for diagnosis and may challenge the 
need for other invasive and time-consuming examinations, such as 
ultrasound. This marker might especially help in cases of adolescents 
and women in the reproductive age, as ultrasound examination is 
not possible due to their virginal status. Moreover, physicians will 
get a very poor quality of the images produced by ultrasonography 
in obese PCOS patients. Other uses of AMH include the prediction 
of body response to treatment and prescribing the appropriate dose of 
gonadotropin.
Testosterone and androsterenedione are produced by the ovaries 
and the adrenal glands, and the enzyme 5a-reductase converts them to 
dihydrotestosterone and tetrahydrocortisol. Since metabolites and by-
products of this steroid hormone have negative consequences and result 
in other metabolic diseases such as liver disease and insulin resistance, 
multiple steroid hormones should be quantified, and their relation to 
each other should be studied. To detect female hyperandrogenism, 
testosterone is measured in routine clinical practice. However, if 
testosterone is the sole clinical investigator, the detection of excess 
androgen can be missed.35 Moreover, in some PCOS patients, the level 
of testosterone can be normal, but androstenedione is relatively high. 
It was investigated that the ratio of testosterone to dihydrotestosterone 
is an adequate co-measurement that helps in the diagnosis of PCOS. 
Mass spectrometry and immunoassays were used to measure the level 
of testosterone to dihydrotestosterone. 
J. Munzker and colleagues conducted one of the most 
sophisticated studies, in which they measured the ratio of testosterone 
to dihydrotestosterone on well characterized and standardized PCOS 
patients, and carried out a detailed assessment. They used liquid 
New markers for the detection of polycystic ovary syndrome 266
Copyright:
©2019 Sharif et al.
Citation: Sharif E, Alwakeel M. New markers for the detection of polycystic ovary syndrome. Obstet Gynecol Int J. 2019;10(4):257‒268. 
DOI: 10.15406/ogij.2019.10.00452
chromatography/mass spectrometry for a comprehensive measurement 
of steroid hormones coupled with anthropometric parameters, as these 
methods showed high sensitivity and specificity, and helped in the 
quantification and evaluation of hormones.26 Hyperandrogenism is 
a key factor that helps in understanding of PCOS, and one way to 
evaluate it is through the measurement of multiple steroid hormones 
and their relation to each other. So, the ratio of testosterone to 
dihydrotestosterone is one of the novel biomarkers in the diagnosis 
of PCOS. 
Copeptin is another novel biomarker used in the diagnosis of 
PCOS. It resembles arginine vasopressin hormone found in human 
and mice. It is known to stabilize vascular tone and fluid balance. 
Due to the difficulty in measuring arginine vasopressin, copeptin is 
used as it is more stable and sensitive. It has the same C-terminal 
part as arginine vasopressin, composed of a glycopeptide of 39 amino 
acids. Enzyme immunoassay is used to measure the levels of copeptin 
via semi-quantitative method, with a sensitivity of 0.09ng/mL. The 
conducted experiment showed a significant difference in copeptin 
levels in PCOS patients compared to healthy individuals, suggesting 
that it can be used a new non-invasive diagnostic tool for PCOS. 
This biomarker has a positive association with insulin resistance 
and cardiometabolic complications as well. Different concentrations 
of copeptin are correlated with the different stages of polycystic 
ovary syndrome, and can be used to predict the consequences of the 
disease.18 
Irisin is a biomarker that was discovered to be responsible for 
the development of white fat and glucose tolerance recently. It is a 
myokine found circulating in serum and plasma of PCOS patients. 
However, sufficient research done regarding this biomarker has not 
been carried out, as it is unstable and easily degraded. So, it cannot 
be considered as a definitive marker in diagnosis of PCOS yet; 
more characterized and well-designed experiments have yet to be 
demonstrated. However, according to the conducted meta-analysis, 
there is a relation between circulating irisin and PCOS; it has been 
found to be higher in the experimental group compared to the control 
group, and it is interconnected with insulin resistance.18 It has also 
been suggested that the increase in irisin level might be due to other 
factors, such as metabolic stress. Irisin is also affected by drugs 
(metformin), obesity and high free androgen index (FAI). It has been 
noted that elevated levels of circulating irisin is associated with insulin 
resistance, hyperandrogenemia and metabolic syndrome. 
Ghrelin is a hormone that influences pituitary gland function by 
secreting hormones. It is also associated with energy homeostasis, cell 
proliferation and replication. It is a glycopeptide that possesses multi-
functions, and is produced by the gastric. There is another hormone 
coded by the same gene as ghrelin, which is obestatin.36 The levels of 
these two hormones are known to be changed in cases of PCOS, due to 
disorders in pituitary hormone secretions. For PCOS to be diagnosed 
based on these two markers, a specific ratio and heir relation to each 
other should be defined. Radioimmunoassay is the method of choice 
in measuring the concentration of ghrelin and obestatin in the serum 
of both experimental group (patients with PCOS) and a control group. 
A specific chemiluminescence assay with high specificity is used to 
measure LH/FSH. It was elucidated that in cases of PCOS, the level 
of ghrelin increases, in comparison to obestatin, which decreases. The 
incompatibility of these two markers is negatively related to LH/FSH. 
It has also been concluded that obestatin and ghrelin contribute to the 
pathogenesis of PCOS.26 
Metastin is a hormone that is involved in multi-metabolic diseases 
including polycystic ovary syndrome. It is also called Kisspeptin. 
KISS-1 is a gene that codes for this hormone at the time of puberty.18 It 
induces the production of gonadotrophin releasing hormone (GnRH), 
which in turn plays a role in ovulation. It is found in males (in testes), 
and in placenta, small intestine and pancreas. It is illustrated that 
metastin hormone tends to be dimorphic in females, but not in males. 
Increased levels of metastin affect the level of lutenizing hormone 
(LH) by increasing it. It is elucidated that the levels of metastin 
hormone rises in non-obese PCOS patients, which can be used as a 
diagnostic marker.37
It has also been observed recently that there is a correlation between 
haptoglobin and PCOS by proteomic studies.38 Hp is a positive marker 
of inflammation that prevents oxidative damage by binding to any free 
hemoglobin. Since oxidative stress and inflammation are involved in 
the development of PCOS, it only makes sense that haptoglobin levels 
are increased in PCOS patients. 
Although there are many proteins which are potential biomarkers 
for PCOS, there has been insufficient research done upon them due 
to their instability and easily degradable nature. Moreover, most of 
them provide useful information for prognosis and disease monitoring 
rather diagnosis. It would, therefore, be most useful to combine 
various markers, and assess them together for a definitive diagnosis. 
Conclusion
PCOS is the most prevalent, complex endocrine disorder of 
the female reproductive system that is influenced by biochemical, 
genetic and environmental factors, and can even lead to long term 
morbidities, such as diabetes and cardiovascular disease. PCOS 
patients often present with hirsutism, sudden weight gain, hormone 
imbalances, oligo/anovulation, polycystic ovaries, hyperinsulinemia, 
hyperandrogenemia, and higher levels of testosterone. Although there 
is no definitive pathophysiology for the disorder, the primary defects 
are attributed to insulin resistance, and luteinizing hormone and 
follicle-stimulating hormone levels, which leads to excess androgen 
and testosterone production; higher levels of LH than FSH also leads 
to anovulation or oligo-ovulation and problems with conception. 
PCOS is diagnosed in patients by excluding all other possible 
endocrinopathies, following the presence of androgenemia, 
androgenism and an/oligoovulation. Although some places rely on the 
appearance of ovaries for diagnosis, various gene, and protein and 
enzyme markers can also be used. The genetic markers investigated 
are the ones associated with regulating insulin function and androgen 
synthesis, and 43 genes isolated have been identified to be related 
to PCOS. However, these genetic markers are not useful for early 
diagnosis, and can only be used to confirm PCOS in patients already 
exhibiting the definitive symptoms. Protein and enzyme markers are 
commonly used for prognosis and patient monitoring to prevent the 
development of the complications of PCOS, such as CVD. Proteins 
of the adipose tissue have been found to be greatly related to insulin 
resistance and the development of PCOS. However, the instability 
and easily degradable nature of enzymes and proteins have prevented 
adequate research from being carried out on them. The diagnosis of 
PCOS, therefore, relies on the analysis of multiple factors. 
Currently, metformin is prescribed to PCOS patients as it has 
been observed to regulate menstruation and increase the chances 
of conception in both androgenic and non-androgenic forms of the 
syndrome.39 A recent approach suggests that the administration of 
myo-inositol, gymnemic acid and L-methylfolate shows a significant 
decrease in testosterone levels, especially in obese/overweight 
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patients.40 Above all, as there is a decreased metabolism in PCOS 
patients, they are advised to maintain an active lifestyle to prevent the 
development of obesity, diabetes, CVD and other morbidities.
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